

- Invoca, a marketing platform for call analytics and automation, closed a $30 million Series D round of funding led by Morgan Stanley Alternative Investment Partners with participation from previous investors Accel Partners, Upfront Ventures, Rincon Venture Partners, Salesforce Ventures, and Stepstone. The company has raised a total of $60 million to date.
- Scentbird, a subscription service for perfumes and cologne, has secured an additional $2.8 million in seed funding. It plans to use the funding to expand its leadership and operations team, and ramp up marketing efforts. Investors in the current seed round include: Eclipse Ventures; Vaizra Investments; Ludlow Ventures; FundersClub; Scrum Ventures; SGH Capital, Alexis Ohanian of Reddit; Michael Seibel of SocialCam; Tikhon Bernstam of Parse and Philip Krim of Casper. The company has raised an aggregate of $3.8 million to date. It raised $1 million in seed funding in August 2015 from Y Combinator; 500 Startups; TMT Investments; Dominion Capital, and several angel investors.
- Amal Therapeutics (Amal) completed CHF 3 million (approximately $3.08 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. The company will use the funds to progress the preclinical development of its lead vaccine (ATP124) for colorectal cancer and to further develop its KISIMA technology platform for therapeutic tumor vaccination.
- PowerInbox, a NYC-based dynamic, real-time and personalized in email technology provider, raised $6.5 million in Series A funding. The round was led by Battery Ventures, Genesis Partners and new investor Maverick Ventures, with participation from previous investors. In conjunction with the funding, Libby Novack, from Maverick Ventures, joined PowerInbox’ board. The company intends to use the funds to increase sales, product development and marketing efforts.
- CLEARink closed a second round of funding. The new investments will enable the company to commercialize its innovative and patented reflective display technology in 3 different applications areas: Electronic Shelf Labels (ESL), Wearable Devices, and Mobile Devices.The initial closing for the current funding round added up to a total of approximately US$7 million, with plans to close up to an additional US$6 million in the next 4 months. The investors in the initial closing include Jinfu, a listed advanced materials company from Suzhou, LangSheng Capital and NEY from Shanghai, as well as Altus Ventures and CrossPacific Capital from Vancouver, Canada.
- ImmuneXcite raised $8.6 million in a Series A financing round as the immuno-oncology biotech announced the addition of Glaxo and Sanofi Genzyme veterans to its executive crew. The Lexington, MA-based company said in a statement that it plans to use the funding to complete studies that will allow it to choose a lead program to start clinical trials. The investors included Cormorant Asset Management, Sanofi Genzyme BioVentures, and Partners Innovation Fund.
- MapD, a startup with a cloud-based data analytics service powered by a GPU-enabled database, secured a $10 million funding round. Nvidia’s GPU Ventures participated in the round, as did Alphabet’s GV venture capital division, and Verizon Ventures. MapD started in 2014 and is based in San Francisco. The round was led by a syndicate headed by Vanedge Capital. Customers include Simulmedia and Verizon.
- Planday, a Danish startup that offers a cloud-based “shift planning” solution for various types of businesses that employ a flexible workforce, such as restaurants, hotels, stores, call centers and gyms, scored $14 million in Series B funding. The round was led by new investor Idinvest, with participation from existing backer Creandum, which led Planday’s Series A round, in addition to SEB Private Equity, and angel investor Arthur Kosten (co-founder of Booking.com).
- Cyara Solutions Corp., provider of the market-leading omni-channel discovery, testing and monitoring platform which helps enterprises accelerate for the delivery of flawless customer experience at scale, secured $25 million in Series A funding in a round led by PeakSpan Capital and Greenspring Associates. The company will use the funds to scale the business and accelerate the company’s fast growth.
- Zavante Therapeutics, Inc., a late clinical-stage biopharmaceutical company, today announced that it closed a $45 million Series A financing, consisting of $35 million from new investors and$10 million from the conversion of outstanding convertible notes. Proceeds from the financing will be used for the development of the Company’s lead product candidate, ZTI-01 (fosfomycin for injection), an injectable antibiotic with a differentiated mechanism of action designed for use in the hospital setting.
If you are interested in being included in our funding roundup, submit your press release or blog post about your financing round to mitos@vator.tv.
Image source: globalfinancialfunding.com